Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Abroad (travel likely)RecruitingPHASE2

Conditions

Mantle Cell Lymphoma · Non Hodgkin Lymphoma · Hematologic Malignancy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

M D Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Preetesh Jain, MD, DM, PhD) · pjain@mdanderson.org · 713-563-8786
Contact: Principal Investigator (Preetesh Jain, MD)

Study leads

Preetesh Jain, MD, DM, PhD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Follicular Lymphoma

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States

CD70-targeted immunoPET Imaging of Malignant Cancers

Renal Cancer · Renal Clear Cell Carcinoma · Lymphoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

B-cell Acute Lymphoblastic Leukemia · Large B-cell Lymphoma · Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Los Angeles, United States

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

Abroad (travel likely)RecruitingPHASE3

Berkeley, United States · Duarte, United States